Epithelial cell cancer drug
US6288045A · kind A · utility
15Cited by
1References
19Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jun 9, 2000 |
| Grant date | Sep 11, 2001 |
| Priority date | — |
| Expiry date | Jun 9, 2020 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method of treating epithelial cell cancer comprising administering to a mammalian patient diagnosed as having an epithelial cell cancer a therapeutically effective amount of 4,5 di-cyclo, disilico, dimagnesium, dialumino, oxyo, trihydrate, or its acetate, sulfate, hydrochlorate, or brominate salts. The composition is synthesized from a naturally occurring non-toxic zeolites, and has a 100% kill rate within 72 hours against buccal mucosa and ling squamous epithelial cell cancers. It is not cytoxic to healthy human cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.